高海女

高海女，女，主任醫師、教授、博士生導師、碩士生導師，畢業於浙江大學醫學院。

現任樹蘭（杭州）醫院感染病科副主任、浙江樹人大學樹蘭國際醫學院教授。

基本介紹

• 中文名：高海女
• 畢業院校：浙江大學 
• 學歷：博士研究生 
• 教學職稱：教授
• 臨床職稱：主任醫師
• 執業地點：樹蘭（杭州）醫院

人物經歷

2000年畢業於浙江大學醫學院，獲學士學位；

2000-2003年畢業於浙江大學醫學院，獲碩士學位；

2003-2005年在浙江大學醫學院附屬第一醫院任住院醫師；

2005年，晉升為主治醫師；

2011-2013年，就讀在職博士研究生；

2013年，晉升感染科副主任醫師；

2016年起任職於樹蘭（杭州）醫院；

2018年，晉升感染科主任醫師、浙江大學兼職博士生導師；

研究方向

各種感染性疾病，包括細菌性、真菌性、病毒性寄生蟲病；各種疑難肝病以及肝衰竭肝移植圍手術期管理，對於重症流感肺炎，腸菌移植治療各種肝病有較深入的研究。

科研成果

[1] Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet, 2013, 381(9881):1916-1925.

[2] Viral genome and antiviral drug sensitivity analysis of two patients from a family cluster caused by the influenza A(H7N9) virus in Zhejiang, China, 2013. International journal of infectious diseases，2014, 29:254-258.

[3] Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nature communications, 2014, 5:3595.

[4] Immune derangement occurs in patients with H7N9 avian influenza. Critical care, 2014, 18(2):R43.

[5] Clinical findings in 111 cases of influenza A (H7N9) virus infection. The New England journal of medicine, 2013, 368(24):2277-2285.

[6] Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clinical infectious diseases, 2014, 58(8):1095-1103.

[7] An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection. BMC infectious diseases, 2014, 14:359.

[8] Successful treatment of avian-origin influenza A(H7N9) infection using convalescent plasma. Int J Infect Dis. 2015, 41: 3-5.

[9] The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes. Sci Rep. 2015 Jun 1;5:10942.

[10] Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia. Crit Care Med. 2016 Jun;44(6):e318-28.

[11] From SARS to MERS: evidence and speculation. Front Med. 2016 Dec;10(4):377-382.

[12] Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus. Clin Infect Dis. 2018 Mar 19;66(7):1054-1060.

[13] HINT: a novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure. Aliment Pharmacol Ther. 2018 Oct;48(7):750-760.

[14] Factors Associated With Fatality Due to Avian Influenza A(H7N9) Infection in China. Clin Infect Dis. 2020 Jun 24;71(1):128-132.

[15] .Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Front Cell Infect Microbiol. 2022 Jan 18;11:761192.

[16]Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe. 2022 Jan 24.

[17] Clinical Risk Score for Invasive Pulmonary Aspergillosis in Patients With Liver Failure: A Retrospective Study in Zhejiang. Front Med (Lausanne). 2021 Nov 22;8:762504.

[18] Prognostic Model and Nomogram Construction Based on a Novel Ferroptosis-Related Gene Signature in Lower-Grade Glioma. Front Genet. 2021 Nov 8;12:753680.

[19] Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe. 2022 Mar;3(3):e193-e202.